Cancer Therapy Advisor11h
Pembrolizumab Plus CRT Provides Durable Tumor Control in NSCLC
Pembrolizumab and concurrent CRT, followed by pembrolizumab consolidation, provided long-term tumor control in previously untreated, unresectable, stage III NSCLC.
Cancer Therapy Advisor21h
States Try to Rein in Health Insurers’ Claim Denials, With Mixed Results
In a survey last year by the American Medical Association, 93% of doctors said that insurers’ prior authorization practices ...
Cancer Therapy Advisor21h
Imfinzi Approved as Perioperative Treatment for MIBC
The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.
Cancer Therapy Advisor21h
High-Dose Chemo and HSCT May Provide Long-Term Benefits for MCL Patients
High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.
Cancer Therapy Advisor21h
FDA Official Quits, Warns of Misinformation
A top official at the FDA is stepping down, warning that the HHS secretary aims to spread misinformation and lies.